Skip to main content

Advertisement

Table 6 Mean change in forward wave amplitude (mmHg) after EMPA therapy separated according to median of different variables at baseline

From: How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial

Variable Age HbA1c Copeptin Heart rate LDL-cholesterol Uric acid Systolic BP hsCRP
≥ median − 1.98 ± 5.31 − 2.14 ± 5.46 − 2.56 ± 5.60 − 1.86 ± 4.94 − 1.95 ± 6.47 − 2.23 ± 5.33 − 0.76 ± 5.10 − 1.31 ± 4.99
< median − 1.19 ± 5.26 − 1.03 ± 5.07 − 0.81 ± 4.90 − 1.29 ± 5.65 − 1.27 ± 4.01 − 1.03 ± 5.21 − 2.30 ± 5.36 − 1.86 ± 5.58
p-value 0.585 0.442 0.225 0.692 0.638 0.406 0.287 0.708
  1. Data are given as mean ± SD
  2. hsCRP high sensitive C-reactive protein, LDL-cholesterol low density lipid cholesterol, heart rate 24-h ambulatory heart rate, systolic BP systolic 24-h ambulatory blood pressure